MyMD Pharmaceuticals gives dosing update on Phase 2 of MYMD-1 trial

MyMD Pharmaceuticals announced a dosing update on its fully-funded Phase 2 clinical trial of lead drug candidate MYMD-1, an orally available next-generation TNF-alpha inhibitor, as a therapy for chronic inflammation associated with sarcopenia and frailty.The Safety Review Committee has confirmed no safety or toxicity issues with the first 30 patients enrolled in this study and has voted unanimously to escalate to the final dose level. Thirty patients enrolled in Cohorts 1, 2, and 3 have completed dosing and end of study visits. To date, three subjects from Cohort 4 have completed end of study visits. There are no outstanding study visits and all 30 patients have officially completed all study parameters and been discharged from the study. "We are proud of the notable progress that we have made thus far on our first Phase 2 study of MYMD-1," said Chris Chapman MD, President, Director, and Chief Medical Officer at MyMD Pharmaceuticals. "As we move into the final cohort of this study, we remain hopeful in MYMD-1’s potential to transform future treatment of sarcopenia/frailty in the aging population."